Andelyn Biosciences

Executive Summary

Andelyn Biosciences is a full-service contract development and manufacturing organization (CDMO) focused exclusively on gene and cell therapy. Headquartered in Columbus, Ohio, the company provides end-to-end viral vector manufacturing services, from process development through commercial-scale cGMP production. Founded in 2020, Andelyn leverages a proprietary technology platform and deep scientific expertise to support partners in developing life-altering genetic medicines. As a privately held, pre-clinical stage company, Andelyn has yet to disclose total funding or valuation, but it operates in the rapidly expanding gene therapy CDMO market, which is projected to grow significantly over the next decade. The company's strategic location in the Midwest allows it to serve a broad base of biotech and pharmaceutical clients while benefiting from regional talent pools and operational cost advantages. Andelyn's competitive positioning relies on its ability to offer flexible, scalable solutions for viral vector production, a critical bottleneck in gene therapy development. However, the CDMO space faces intense competition from larger players and rising client demands for reduced timelines and cost efficiencies. Andelyn's success will depend on securing long-term partnerships, expanding capacity, and maintaining high-quality standards. The company's pre-clinical stage suggests limited public financial data, making investment evaluation challenging but not uncommon for emerging CDMOs. Key risks include technology obsolescence, regulatory changes, and potential supply chain disruptions. Despite these challenges, Andelyn's focus on the high-growth gene therapy sector and its comprehensive service offering position it as a promising player in the CDMO landscape.

Upcoming Catalysts (preview)

• Q2 2026Announcement of Strategic Partnership with a Major Gene Therapy Developer65% success
• Q4 2026Completion of New GMP Manufacturing Facility Expansion70% success
• Q3 2026FDA Clearance of IND for a Partner's Gene Therapy Product Using Andelyn's Vectors45% success